Phase I Protocol to Assess Safety of Biomarker-Driven Therapy Using Selective Immune Activators in Combination With Anti-PD-1 (Nivolumab) in Patients With First Recurrence of Glioblastoma
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Dec 2018
At a glance
- Drugs Epacadostat (Primary) ; Ipilimumab (Primary) ; MK 4166 (Primary) ; Nivolumab (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions
- 11 Dec 2018 Planned End Date changed from 1 Nov 2023 to 1 Jan 2024.
- 11 Dec 2018 Planned primary completion date changed from 1 Nov 2021 to 1 Jan 2022.
- 11 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 1 Jan 2019.